Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: Results of a double-blind, multicentre, randomized study

Diabetes, Obesity and Metabolism

Volumn 8, Issue 2, 2006, Pages 164-174

  Davidson, Jaime A ^a   Perez, A ^b   Zhang, J ^b  

^a Endocrine and Diabetes Associates of Texas   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Insulin; Insulin resistance; Pioglitazone; Type 2 diabetes

Indexed keywords

FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; PLACEBO; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DISEASE DURATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; LEG EDEMA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 33645996039     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00499.x     Document Type: Article

References (21)

1. Wulffele MG, Kooy A, Lehert P et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25: 2133-2140.
2. Turner RC, Cull CA, Frighi V, Holman RR for the UK Prospective Diabetes Study Group (UKPDS). Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes. JAMA 1999; 281: 2005-2012.
3. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002; 347: 1342-1349.
4. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002; 287: 360-372.
5. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000; 321: 405-412.
6. Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-828.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853. Erratum in: Lancet 1999; 354: 602.
8. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes mellitus: A six-month, randomized, placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605-1611.
9. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. Clin Ther 2002; 22: 1395-1409.
10. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111: 10-17.
11. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, and the Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: A randomized, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Prac t 2002; 56: 251-257.
12. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH, QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141-147.
13. American Diabetes Association. Screening for type 2 diabetes. Clinical practice recommendations 1999. Diabetes Care 1999; 22 (Suppl. 1): S20-S23.
14. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of symptoms for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981; 64: 1227-1234.
15. Haffner SM, American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27 (Suppl. 1): S68-S71.
16. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl. 1): S5-S20.
17. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J, Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-1232.
18. Perez A, Khan M, Johnson T, Karunaratne M. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diabetes Vasc Dis Res 2004; 1: 44-50.
19. Scheen A. Combined thiazolidinedione-insulin therapy. Should we be concerned about safety? Drug Safety 2004; 27: 841-856.
20. Strowig SM, Aviles-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 2004; 27: 1577-1583.
21. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A, PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: 1647-1653.